Warren Daniel S, Zachary Andrea A, Sonnenday Christopher J, King Karen E, Cooper Matthew, Ratner Lloyd E, Shirey R Sue, Haas Mark, Leffell Mary S, Montgomery Robert A
The Department of Surgery, The Johns Hopkins University School of Medicine, Balitmore, Maryland, USA.
Am J Transplant. 2004 Apr;4(4):561-8. doi: 10.1111/j.1600-6143.2004.00364.x.
ABO incompatibility and human leukocyte antigen (HLA) sensitization remain the two largest barriers to optimal utilization of kidneys from live donors. Here we describe the first successful transplantation of patients who were both ABO incompatible and crossmatch positive with their only available donor. A preconditioning regimen of plasmapheresis (PP) and low-dose CMV hyperimmune globulin (CMVIg) was delivered every other day until donor-specific antibody (DSA) titers were reduced to a safe level and isoagglutinin titers were < or =16. Each patient received quadruple sequential immunosuppression, splenectomy and three protocol post-transplant PP/CMVIg treatments. There was no hyperacute rejection. Two of the three patients had a persistent positive cytotoxic crossmatch on the day of transplant and eliminated their DSA subsequently. Antibody-mediated rejection (AMR) in one patient was reversed by reinitiating PP/CMVIg and anti-CD20. The patients are more than 9 months post-transplant with excellent graft function. Preconditioning with PP/CMVIg results in a durable suppression of DSA and permits accommodation of the allograft to a discordant blood type. The ability to cross these two barriers simultaneously is clinically important as sensitized patients have often exhausted their blood type compatible living donors during previous transplants.
ABO血型不相容和人类白细胞抗原(HLA)致敏仍然是活体供肾最佳利用的两大主要障碍。在此,我们描述了首例与唯一可用供体ABO血型不相容且交叉配型呈阳性的患者成功进行移植的案例。每隔一天进行一次血浆置换(PP)和低剂量巨细胞病毒高免疫球蛋白(CMVIg)的预处理方案,直到供体特异性抗体(DSA)滴度降至安全水平且同种凝集素滴度≤16。每位患者接受四联序贯免疫抑制、脾切除术以及三次移植后方案规定的PP/CMVIg治疗。未发生超急性排斥反应。三名患者中有两名在移植当天细胞毒性交叉配型持续呈阳性,随后清除了他们的DSA。通过重新启动PP/CMVIg和抗CD20逆转了一名患者的抗体介导排斥反应(AMR)。患者移植后已超过9个月,移植肾功能良好。PP/CMVIg预处理可持久抑制DSA,并使同种异体移植物适应不相合的血型。同时跨越这两大障碍的能力在临床上具有重要意义,因为致敏患者在先前的移植过程中往往已用尽与其血型相容的活体供体。